Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous MESO CAR NK cells
- Development stage
- Unknown
- Lead developer
- Zhuhai People's Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous MESO CAR NK cells are an investigational cell therapy consisting of natural killer (NK) cells derived from the patient and genetically engineered to express a chimeric antigen receptor (CAR) targeting mesothelin (MESO). Mesothelin is a cell-surface glycoprotein highly expressed in various solid tumors, including epithelial ovarian carcinoma, while maintaining low expression in normal tissues. This therapy combines the innate anti-tumor activity of NK cells with the antigen-specific targeting provided by the CAR construct. It is currently being investigated in early-phase clinical trials for patients with refractory epithelial ovarian carcinoma who have failed or relapsed after standard therapies.
- Other names
- autologous mesothelin-targeted CAR NK cellsMESO CAR-NK cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on autologous MESO CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous MESO CAR NK cells.